Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial.

[1]  F. Martinez,et al.  Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.

[2]  J. Curtis,et al.  Glucocorticoid-Augmented Efferocytosis Inhibits Pulmonary Pneumococcal Clearance in Mice by Reducing Alveolar Macrophage Bactericidal Function , 2015, The Journal of Immunology.

[3]  F. Martinez,et al.  Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. , 2015, Annals of the American Thoracic Society.

[4]  P. Scanlon,et al.  Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? , 2015, American journal of respiratory and critical care medicine.

[5]  Kayleigh Kew,et al.  Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. , 2014, The Cochrane database of systematic reviews.

[6]  Sanjay Sethi,et al.  Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. , 2013, The Journal of infectious diseases.

[7]  F. Martinez,et al.  The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol , 2012, European Respiratory Journal.

[8]  Theresa M. Ames,et al.  Glucocorticoids Relieve Collectin-Driven Suppression of Apoptotic Cell Uptake in Murine Alveolar Macrophages through Downregulation of SIRPα , 2012, The Journal of Immunology.

[9]  A. Sharafkhaneh,et al.  Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. , 2012, Respiratory medicine.

[10]  T. Seemungal,et al.  Reported pneumonia in patients with COPD: findings from the INSPIRE study. , 2011, Chest.

[11]  P. Jones,et al.  Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results , 2009, European Respiratory Journal.

[12]  A. Anzueto,et al.  Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes , 2009, COPD.

[13]  M. Peters-Golden,et al.  Eff erocytosis impairs pulmonary macrophage and lung antibacterial function via PGE 2 / EP 2 signaling , 2009 .

[14]  T. Murphy,et al.  Infection in the pathogenesis and course of chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[15]  W. Janssen,et al.  Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha. , 2008, American journal of respiratory and critical care medicine.

[16]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. , 2008, Respiratory medicine.

[17]  A. Anzueto,et al.  Effect of fluticasone propionate/salmeterol (250/50 g) or salmeterol (50 g) on COPD exacerbations , 2008 .

[18]  N. McElvaney,et al.  Epithelial expression of TLR4 is modulated in COPD and by steroids, salmeterol and cigarette smoke , 2007, Respiratory research.

[19]  Robert A Wise,et al.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.

[20]  T. Goldmann,et al.  Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients , 2005, Respiratory research.

[21]  W. Thompson,et al.  The Burden of Community-Acquired Pneumonia in Seniors: Results of a Population-Based Study , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  S. Rooney,et al.  Pulmonary surfactant secretion in briefly cultured mouse type II cells. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[23]  J. Whitsett,et al.  Pulmonary collectins and innate host defense of the lung. , 2001, Microbes and infection.

[24]  D. Voelker,et al.  KGF increases SP-A and SP-D mRNA levels and secretion in cultured rat alveolar type II cells. , 1998, American journal of respiratory cell and molecular biology.

[25]  J. Vestbo,et al.  Risk factors for death and hospitalization from pneumonia. A prospective study of a general population. , 1995, The European respiratory journal.

[26]  DifcoTM HycheckTM,et al.  The package insert. , 1969, JAMA.